Piper Sandler Reiterates Buy Rating on AbbVie Inc. (NYSE: ABBV)
Piper Sandler maintains its buy rating on AbbVie with a $298 price target, a 23% upside from the current price.
Key Points
- Piper Sandler reiterated its buy rating on AbbVie Inc. (ABBV) with a target price of $298 on June 23, 2026.
- Piper Sandler's $298 price target implies 23% upside from AbbVie Inc.'s ($ABBV) current $242.28 share price.
- Shares of AbbVie traded near $234.93 on Tuesday, with a market cap of approximately $406.38 billion.
- Multiple insiders purchased shares on May 8, 2026, while analysts like Canaccord Genuity maintained buy ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Piper Sandler reiterated its buy rating on AbbVie Inc. (NYSE: ABBV) on June 23, 2026, maintaining a price target of $298. This comes as the company's shares traded near $234.93 on Tuesday.
Piper Sandler vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Analysts Set New Price Targets
On June 23, 2026, Piper Sandler reiterated its buy rating on AbbVie with a price target of $298. Canaccord Genuity also maintained a buy rating on the same day with a target of $273. Earlier, on May 15, Evercore ISI Group maintained its buy rating, setting a target of $235. Overall, AbbVie holds a consensus buy recommendation with an average target price of $253.55 based on 29 analyst opinions.
AbbVie Inc. Stock Down 5.2%
Shares of AbbVie Inc. (NYSE: ABBV) traded near $234.93 on Tuesday. The company has a market cap of about $406.38 billion and a forward P/E ratio of 14.16. Its beta is 0.309, indicating lower volatility compared to the market. The stock's 52-week range is between $181.73 and $244.81, with a 50-day moving average of $211.77 and a 200-day moving average of $220.57.
$ABBV price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at AbbVie Inc.
On May 8, 2026, several insiders, including Frederick Waddell, William H.L. Burnside, Thomas Falk, Roxanne Austin, Edward Rapp, and Brett Hart, each bought 1,118 shares of AbbVie. These transactions were not part of any pre-arranged trading plans.
About AbbVie Inc.
AbbVie Inc., headquartered in North Chicago, Illinois, is a global biopharmaceutical company engaged in the research, development, manufacture, and sale of medicines and therapies. The company offers treatments for autoimmune diseases, cancers, and neurological disorders, among others. With a workforce of 57,000 employees, AbbVie is led by CEO Robert A. Michael, CPA.
Bottom Line
Piper Sandler's reiterated buy rating on AbbVie Inc. highlights continued analyst confidence in the company's potential. With a robust market position and diverse product offerings, AbbVie remains a key player in the healthcare sector. Investors should note that analyst ratings are forward-looking opinions and may not reflect current market conditions or company performance.
Get AbbVie Inc. alerts
New 13F filings, insider trades, and analyst moves on $ABBV, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.